CONTEXT: The stages of the menopause transition are characterized by changes in ovarian hormones and increased cardiovascular disease (CVD) risk factors and vasomotor symptoms that may adversely affect vascular health. OBJECTIVE: We tested the hypothesis that endothelial function, a predictor of CVD, would be reduced across the stages of the menopause transition, independent of CVD risk factors and vasomotor symptoms. DESIGN, SETTING, AND PARTICIPANTS: This was a cross-sectional study of 132 healthy women from the general community aged 22-70 yr, categorized as premenopausal (n = 33, 32 ± 6 yr; mean ± SD), early perimenopausal (n = 20, 49 ± 3 yr) or late perimenopausal (n = 22, 50 ± 4 yr), or early (n = 30, 55 ± 3 yr) or late postmenopausal (n = 27, 61 ± 4 yr). MAIN OUTCOME: Endothelial-dependent vasodilation was measured by brachial artery flow-mediated dilation (FMD) using ultrasound. RESULTS: Brachial artery FMD was significantly different among the groups (P < 0.001). It was highest in premenopausal women (9.9 ± 2.1%) with progressive decrements in perimenopausal (early: 8.2 ± 2.5%; late: 6.5 ± 1.9%) and postmenopausal women (early: 5.5 ± 1.9%; late: 4.7 ± 1.7%). Adjustment for risk factors, vasomotor symptoms, and sex hormones did not alter the association (P < 0.001). In subgroup analyses of women aged 50-59 yr, brachial artery FMD was lower in late peri- and early and late postmenopausal compared with early perimenopausal women (P < 0.001) but was not different between late perimenopausal and either early or late postmenopausal women. CONCLUSIONS: Our findings suggest that a decline in endothelial function begins during the early stages of menopause (perimenopause) and worsens with the loss of ovarian function and prolonged estrogen deficiency. These data add to the accumulating evidence that the perimenopausal window is a critical time period for adverse changes in CVD risk.
CONTEXT: The stages of the menopause transition are characterized by changes in ovarian hormones and increased cardiovascular disease (CVD) risk factors and vasomotor symptoms that may adversely affect vascular health. OBJECTIVE: We tested the hypothesis that endothelial function, a predictor of CVD, would be reduced across the stages of the menopause transition, independent of CVD risk factors and vasomotor symptoms. DESIGN, SETTING, AND PARTICIPANTS: This was a cross-sectional study of 132 healthy women from the general community aged 22-70 yr, categorized as premenopausal (n = 33, 32 ± 6 yr; mean ± SD), early perimenopausal (n = 20, 49 ± 3 yr) or late perimenopausal (n = 22, 50 ± 4 yr), or early (n = 30, 55 ± 3 yr) or late postmenopausal (n = 27, 61 ± 4 yr). MAIN OUTCOME: Endothelial-dependent vasodilation was measured by brachial artery flow-mediated dilation (FMD) using ultrasound. RESULTS:Brachial artery FMD was significantly different among the groups (P < 0.001). It was highest in premenopausal women (9.9 ± 2.1%) with progressive decrements in perimenopausal (early: 8.2 ± 2.5%; late: 6.5 ± 1.9%) and postmenopausal women (early: 5.5 ± 1.9%; late: 4.7 ± 1.7%). Adjustment for risk factors, vasomotor symptoms, and sex hormones did not alter the association (P < 0.001). In subgroup analyses of women aged 50-59 yr, brachial artery FMD was lower in late peri- and early and late postmenopausal compared with early perimenopausal women (P < 0.001) but was not different between late perimenopausal and either early or late postmenopausal women. CONCLUSIONS: Our findings suggest that a decline in endothelial function begins during the early stages of menopause (perimenopause) and worsens with the loss of ovarian function and prolonged estrogen deficiency. These data add to the accumulating evidence that the perimenopausal window is a critical time period for adverse changes in CVD risk.
Authors: Georgina E Hale; Xue Zhao; Claude L Hughes; Henry G Burger; David M Robertson; Ian S Fraser Journal: J Clin Endocrinol Metab Date: 2007-06-05 Impact factor: 5.958
Authors: Karen A Matthews; Sybil L Crawford; Claudia U Chae; Susan A Everson-Rose; Mary Fran Sowers; Barbara Sternfeld; Kim Sutton-Tyrrell Journal: J Am Coll Cardiol Date: 2009-12-15 Impact factor: 24.094
Authors: Rebecca C Thurston; Kim Sutton-Tyrrell; Susan A Everson-Rose; Rachel Hess; Karen A Matthews Journal: Circulation Date: 2008-09-02 Impact factor: 29.690
Authors: MaryFran R Sowers; Huiyong Zheng; Daniel McConnell; Bin Nan; Siobán D Harlow; John F Randolph Journal: J Clin Endocrinol Metab Date: 2008-07-22 Impact factor: 5.958
Authors: Daniel J Green; Maria T E Hopman; Jaume Padilla; M Harold Laughlin; Dick H J Thijssen Journal: Physiol Rev Date: 2017-04 Impact factor: 37.312
Authors: Yasina B Somani; James A Pawelczyk; Mary Jane De Souza; Penny M Kris-Etherton; David N Proctor Journal: Am J Physiol Heart Circ Physiol Date: 2019-06-07 Impact factor: 4.733
Authors: S Lennon-Edwards; M G Ramick; E L Matthews; M S Brian; W B Farquhar; D G Edwards Journal: Nutr Metab Cardiovasc Dis Date: 2014-05-24 Impact factor: 4.222
Authors: Megan M Wenner; Kelly N Sebzda; Andrew V Kuczmarski; Ryan T Pohlig; David G Edwards Journal: Am J Physiol Regul Integr Comp Physiol Date: 2017-04-24 Impact factor: 3.619